OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Kuykendall on the Efficacy of Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

January 9th 2024

Andrew Kuykendall, MD, discusses the efficacy of pelabresib plus ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Dr Lee on the Updated Efficacy and Safety Data for Linvoseltamab in R/R Multiple Myeloma

January 9th 2024

Hans C. Lee, MD, discusses updated data from the phase 2 LINKER-MM1 study evaluating linvoseltamab in patients with relapsed/refractory multiple myeloma.

Dr Jonasch on the Importance of Spotlighting Patient Advocacy in GU Malignancies

January 8th 2024

Eric Jonasch, MD, discusses the goals of a meeting sponsored by the International Kidney Cancer Coalition that will focus on patient advocacy in GU malignancies.

Dr Chiang on Managing Advanced NSCLC Without Driver Mutations

January 8th 2024

Anne Chiang, MD, PhD, discusses treating patients with advanced non–small cell lung cancer without driver mutations.

Dr Novik on Emergent Treatment Options in ER+ Breast Cancer

January 8th 2024

Yelena Novik, MD, discusses advancements and emerging trends that have been seen in the treatment of patients with advanced estrogen-receptor–positive breast cancer, citing clinical trials that have helped push the treatment armamentarium forward.

Dr Sumrall on the Clinical Efficacy of ONC201 in H3K27M -Mutant Diffuse Midline Gliomas

January 8th 2024

Ashley Sumrall, MD, FACP, medical oncologist, section chief, Neuro-Oncology, clinical assistant professor, medicine, Atrium Health, Levine Cancer Institute, discusses the clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas.

Dr Vergote on the Efficacy of Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

January 8th 2024

Ignace B. Vergote, MD, PhD, discusses the efficacy of tisotumab vedotin-tftv in patients with recurrent or metastatic cervical cancer, according to data from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628).

Dr Wander on Genomic Alterations in ER+/HER2– Metastatic Breast Cancer

January 5th 2024

Seth Wander, MD, PhD, discusses findings from an analysis of baseline genomic alterations in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who were enrolled in the single-arm, phase 2 ELAINE-2 trial of lasofoxifene plus abemaciclib.

Dr Naik on the Evolving Role of Bispecific Antibodies in Multiple Myeloma

January 5th 2024

Seema G. Naik, MD, discusses the evolving role of bispecific antibodies in hematologic malignancies.

Dr Ferrajoli on the Incidence of Hypertension in Patients With CLL Receiving Acalabrutinib

January 5th 2024

Alessandra Ferrajoli, MD, discusses the rationale for, and findings from, a cumulative review of hypertension in patients with chronic lymphocytic leukemia and other hematologic malignancies who received acalabrutinib.

Dr Gay on Efficacy Findings From the IsKia Trial in Multiple Myeloma

January 5th 2024

Francesca Gay, MD, PhD, discusses the safety and efficacy findings derived from the phase 3 IsKia trial in patients with newly diagnosed multiple myeloma.

Dr Sartor on Efficacy and Safety of Lutetium Lu 177 Vipivotide Tetraxetan in Taxane-Naive mCRPC

January 5th 2024

Oliver Sartor, MD, discusses updated efficacy findings from the phase 3 PSMAfore trial of lutetium Lu 177 vipivotide tetraxetan in patients with previously treated, taxane-naive metastatic castration-resistant prostate cancer.

Dr Ip on the Importance of NGS Testing in Hematologic Malignancies

January 5th 2024

Andrew Ip, MD, discusses findings from a study on the use of next-generation sequencing of flow cytometry CD markers and machine learning as a replacement to flow cytometry analysis for the diagnosis of hematologic neoplasms.

Dr Bartsch on the TUXEDO-1 Trial of T-DXd in HER2+ Breast Cancer With Brain Metastases

January 5th 2024

Rupert Bartsch, MD, discusses findings from the final analysis of the phase 2 TUXEDO-1 trial of trastuzumab deruxtecan in patients with HER2-positive breast cancer with active brain metastases.

Dr Ailawadhi on Iopofosine I-131 in Waldenström Macroglobulinemia

January 5th 2024

Sikander Ailawadhi, MD, oncologist, Department of Hematology, CAR T-Cell Therapy Program, Mayo Clinic, discusses how the investigational agent iopofosine I-131 may address unmet needs for patients with Waldenström macroglobulinemia.

Dr He on the Evaluation of Camrelizumab Plus Rivoceranib in Unresectable HCC

January 4th 2024

Aiwu Ruth He, MD, PhD, discusses the evaluation of camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.

Dr Necchi on the Efficacy of TAR-200 Monotherapy in BCG-Unresponsive NMIBC

January 4th 2024

Andrea Necchi, MD, discusses results from the phase 2b SunRISe-1 trial of TAR-200 in patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer.

Dr Leslie on the Significance of the FDA Approval of Pirtobrutinib in Pretreated CLL and SLL

January 4th 2024

Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr Hill on the Use of Carfilzomib With R-CHOP in DLBCL

January 4th 2024

Brian T. Hill, MD, PhD, discusses the final results from a phase 1/2 trial of carfilzomib given with R-CHOP in the frontline setting for patients with non-germinal center diffuse large B-cell lymphoma.

Dr Sallman on the Rationale For Investigating Fedratinib in MDS/MPN Overlap Syndromes

January 4th 2024

David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia.